AI assistant
Supriya Lifescience Limited — Earnings Release 2025
Jan 27, 2025
59375_rns_2025-01-27_9e870292-df19-476b-91b3-f080b2c229f2.pdf
Earnings Release
Open in viewerOpens in your device viewer
==> picture [426 x 68] intentionally omitted <==
Date: January 27, 2025
To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street, Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543434 Scrip Symbol: SUPRIYA
Dear Sir/Madam,
- Subject: Revised Press Release Unaudited Financial Results for the quarter and nine months ended December 31, 2024
Please find attached the revised Press Release with regard to the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024.
Kindly take the same on record and acknowledge the receipt.
Thanking you,
For Supriya Lifescience Limited Digitally signed by SHWETA SHIVDHARI SINGH SHWETA DN: c=IN, o=PERSONAL, pseudonym=5ed61118f9524963913aab8b2dd2f 858, 2.5.4.20=7ecd6cc212b10d907bb2883c588d6eb1 SHIVDHARI d1f28d80e13dba2ebd6975df438869e5, postalCode=400097, st=Maharashtra, serialNumber=b696ab674736edaacabe9d4e9a6 3ae406ea0e6dd83072b0cf6fa56593bffa9dd, cn=SHWETA SHIVDHARI SINGH SINGH Date: 2025.01.27 10:03:19 +05'30' Shweta Singh Company Secretary & Compliance Officer Membership No.: A44973
Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com
Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: [email protected]
GOVT. RECOGNISED EXPORT HOUSE
==> picture [164 x 56] intentionally omitted <==
Press Release for immediate distribution
Supriya Lifescience Q3FY25 PAT Jumps 57% YoY to Rs 46.78 Crore
Mumbai, 27th January 2025: The unaudited financial statements for the Q3FY25 results have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 86 countries across the globe.
Key Consolidated Financial Highlights:
==> picture [347 x 197] intentionally omitted <==
----- Start of picture text -----
Particulars Q3 FY25 Q3 FY24
Revenues (in Rs Cr) 185.65 140.07
Gross Profit (in Rs Cr) 123.87 85.45
EBITDA (in Rs Cr) 65.95 41.49
EBITDA Margin 35.50% 29.60%
PAT (in Rs Cr) 46.78 29.78
PAT Margin 25.2% 21.30%
Quarterly EPS (in Rs) 5.82 3.70
----- End of picture text -----
Key Highlights for Q3 FY25:
In the third quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 33% year-over-year increase, reaching Rs. 185.65 crore compared to Rs. 140.07 crore in Q3 FY24.
Gross Profit for Q3 FY25 stood at Rs. 123.87 crore, with a growth of 45% compared to Rs. 85.45 crore in Q3 FY24.
EBITDA for Q3 FY25 stood at Rs. 65.95 crore, with an EBITDA Margin of 35.50%, as opposed to an EBITDA of Rs. 41.49 crore in Q3 FY24 with an EBITDA margin of 29.60%. This marks an improvement of 591 bps YoY.
The Profit After Tax (PAT) increased by 57% for Q3 FY25 to Rs 46.78 crore, compared to Rs 29.78 crore in Q3 FY24.
The PAT Margin stood at 25.2% in Q3 FY25, compared to 21.30% in Q3 FY24.
Dr. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience Ltd , commenting on the results, said, “Our Q3FY25 results underscore Supriya Lifescience’s commitment to delivering value through operational excellence and strategic growth initiatives. The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments. The steady improvement in our EBITDA and PAT margins, reaching 35% and 25% respectively, highlights our ability to maintain profitability while investing in sustainable growth."
............................................................................................................................................
Disclaimer Statements in this “Document” describing the company’s objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be "forward-looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forwardlooking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments or circumstances after the date hereof.
About Supriya Lifescience Ltd.:
Supriya Lifescience Ltd., a world-renowned producer of active pharmaceutical ingredients, was founded in 1987. Our cutting-edge facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company is headquartered in Mumbai, India, and our facility is located in Khed, District Ratnagiri. Our globally compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA) are supported by robust R&D, eight active CEPs, and fourteen active USDMFs. EHS requirements and ethical principles guide our core business. The company's primary focus is to build intermediates and APIs for innovators and generic firms. We also exclusively collaborate with partners in the capacity of CMOs.
For more details, contact:
Abhishek Chawande: [email protected] | 9664516774 Sanjukta Ghadge : [email protected] | 98926 89895